



## IBA ANNOUNCES DEMAND FOR HIGH CAPACITY CYCLOTRONS CONTINUES TO GROW

*The IBA Cyclone® KIUBE 300 has the highest production capacity ever reached with a PET cyclotron with a production of up to 300 FDG\* doses in two hours.*

**Louvain-la-Neuve, Belgium, June 21<sup>st</sup> 2018** - IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of solutions for the diagnosis and treatment of cancer, announces it will deliver three new Cyclone® KIUBE units in its higher power configuration, 300µA, in Saudi Arabia, the Netherlands and America.

Since launch in 2016, IBA has sold more than 25 Cyclone® KIUBE units and has established the Cyclone® KIUBE as the mid-energy cyclotron of choice due to its power and compact size. UZ Brussel, a hospital in Belgium, recently reported excellent production results from its Cyclone® KIUBE 300 ([more info](#)).

The Cyclone® KIUBE is available in four configurations: 100µA, 150µA, 180µA and 300µA – granting users considerable production flexibility. Users can start with the Cyclone® KIUBE 100 while maintaining the ability to increase their PET Center's capacity over time, allowing them to benefit from the cyclotron's best-in-class technology and meet the increasing demand for FDG\*.

“The IBA Cyclone® KIUBE 300 is the first compact industrial mid-energy cyclotron capable of such performances,” said **Dr Muhammad Sarfaraz Mirza, Business Line Manager at Attieh Medico in Saudi Arabia**. “It will allow us to reach higher levels of production while retaining the flexibility to alter our FDG production, as well as granting us the capacity to produce a large portfolio of non-conventional radioisotopes.”

“We have been using IBA cyclotrons since 1997. The cyclotrons demonstrate market leading reliability and the customer support we receive from IBA is excellent,” said **Erik Van Lier, Managing Director BV Cyclotron VU, Amsterdam, the Netherlands**. “It was therefore an obvious choice to purchase two new Cyclone® KIUBE cyclotrons, 180µA and 300µA, considering their outstanding performance and technology.”

IBA RadioPharma Solutions will be exhibiting at the upcoming SNMMI 2018 Annual Meeting (Society of Nuclear Medicine and Molecular Imaging) in Philadelphia, Pennsylvania, June 23–26, 2018 at booth #548. Attend the Cyclone® KIUBE 300 [poster presentation](#) on June 24, 4pm room 103C.

*\*fluorodeoxyglucose labelled with F-18 is the most commonly used radiotracer in positron emission molecular imaging.*

\*\*\*ENDS\*\*\*



### About the Cyclone® KIUBE

Cyclone® KIUBE is a fixed-energy cyclotron that accelerates negative ions up to 18 MeV and that host up to two proton sources. Designed to deliver, Cyclone® KIUBE offers the highest production capacity ever reached with a PET cyclotron. It is able to produce up to 300 FDG doses in a 2-hour run. Designed for you, Cyclone® KIUBE is also available with a self-shielding option. Designed for ever, Cyclone® KIUBE is upgradable like no other cyclotron, so you can increase your production capacity. A full range of Nirta® targets are available giving you access to <sup>18</sup>F, <sup>13</sup>N, <sup>15</sup>O, <sup>11</sup>C, <sup>18</sup>F2, <sup>68</sup>Ga,...

The Cyclone KIUBE received the CNSC Class II Prescribed Equipment Certification.

For more info, please visit our [website](#).

### About IBA Radiopharma Solutions

Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them with global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers

### About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at [www.iba-worldwide.com](http://www.iba-worldwide.com)

### For further information, please contact:

#### IBA

**Rebecca Lo bue**

Marketing Director

Rebecca.lobue@iba-group.com